'Will not apologise,' says Rahul Gandhi over 'rape in India' remark row

News Network
December 13, 2019

New Delhi, Dec 13: The Lok Sabha and the Rajya Sabha on Friday witnessed uproar as BJP lawmakers demanded an apology from Congress leader Rahul Gandhi over his "rape in India" remark.

Amid the ruckus, Parliamentary Affairs Minister Pralhad Joshi said in the Lower House, "Rahul Gandhi is telling rape in India and it means what? He is asking all the outsiders to come and rape women. Is it right?"

Union Minister Smriti Irani, who defeated the Congress leader in his home bastion Amethi in 2019 Lok Sabha poll, said: "This is the first time in history that a leader is giving a clarion call that Indian women should be raped. Is this Rahul Gandhi's message to the people of the country?"

BJP lawmakers stood and raised slogans demanding an apology from the former Congress president.

In a quick response, Rahul Gandhi said: “I will not apologise. BJP just want to deflect attention from protests in North East.”

Ally DMK's Kanimozhi sided with Gandhi and defended his remark in the House. "PM said 'Make in India', which we respect, but what is happening in country? That is what Rahul Gandhi intended to say. Unfortunately, 'Make in India' is not happening and women in the country are being raped. This is a concern." she said amid pandemonium.

Later, Speaker Om Birla adjourned the proceedings in the Lower House till 12 pm today.

A similar scenario was witnessed in the Upper House with BJP members raising slogans of, "Rahul Gandhi maafi maango" (Rahul Gandhi, apologise)." House Chairman and Vice President M Venkaiah Naidu, however, quelled the protests by asking members to not disturb the proceedings.

"You cannot take the name of a person who is not a member of this House. Nobody has the business to disturb the House," said Naidu. Soon after, he adjourned the Rajya Sabha till 12 noon.

Addressing a poll rally in Jharkhand on Thursday, Gandhi had said Prime Minister Narendra Modi had launched 'Make in India' but nowadays it is 'Rape in India'.

"Narendra Modi had said 'Make in India' but nowadays wherever you look, it is 'Rape in India'. In Uttar Pradesh Narendra Modi's MLA raped a woman, then she met with an accident but Narendra Modi did not utter a word," he had said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country.

Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on Covid-19.

"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.

As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, 'Covishield', on healthy adults in India,  the officials said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for Covid-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine. 

Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.

To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 22,2020

New Delhi, Jun 22: India's COVID-19 cases per lakh people is one of the lowest in the world despite its high population density, and the recovery rate has now reached almost 56 per cent, the Union Health Ministry said on Monday.

For every one lakh population, there are 30.04 coronavirus cases in India, while the global average is over three times at 114.67, the ministry said, referring to the WHO Situation Report 153, dated June 21.

“This low figure is thus a testimony to the graded, pre-emptive and pro-active approach the Government of India along with the states and UTs took for prevention, containment and management of COVID-19," the ministry said in a statement.

Citing the WHO Situation Report, the ministry said the US has 671.24 cases per lakh population, while Germany, Spain, Brazil and the UK have 583.88, 526.22, 489.42 and 448.86 cases per lakh population, respectively.

It said Russia has 400.82 cases per lakh people, while Italy, Canada, Iran and Turkey have 393.52, 268.98, 242.82 and 223.53, respectively.

Coming back to India, as on Monday morning, the total number of coronavirus cases stood at 4,25,282 and the death toll at 13,699, according to figures issued by the ministry.

In its update issued at 8 AM Monday, the ministry said 9,440 COVID-19 patients recovered in the last 24 hours, taking the total number of recoveries to 2,37,195, a recovery rate of 55.77 per cent.

Presently, there are 1,74,387 active cases and all are under medical supervision, it said.

"The difference between the recovered patients and the active COVID-19 cases continues to widen. Today, the number of recovered patients has crossed the number of active patients by 62,808," the ministry said.

The COVID-19 testing infrastructure is continuously being ramped up and number of government labs has been increased to 723 and the private labs to 262, adding up to a total of 985, it said.

According to the Indian Council of Medical Research, a total of 69,50,493 samples have been tested up to 21 June, 1,43,267 of them just on Sunday.

On Monday, the country added 14,821 new COVID-19 cases in a single day, pushing the tally to 4,25,282, while the death toll rose to 13,699 with 445 new fatalities reported till 8 am.

The country breached the four lakh-mark on Sunday, eight days after crossing three lakh COVID-19 cases. It has recorded 2,34,747 infections since June 1.

Monday was the 11th day in a row when the country registered over 10,000 cases.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 22,2020

New Delhi, Jan 22: Delhi Chief Minister Arvind Kejriwal has assets worth Rs 3.4 crore, an increase of Rs 1.3 crore from 2015, according to his election affidavit.

Kejriwal's total assets were worth Rs 2.1 crore in 2015.

The cash and fixed deposits of Kejriwal's wife Sunita Kejriwal increased from Rs 15 lakh in 2015 to Rs 57 lakh in 2020.

A party functionary said Rs 32 lakh worth cash and fixed deposits have been received by Sunita Kejriwal as voluntary retirement benefits while the rest are savings.

The cash and fixed deposits of the chief minister increased from Rs 2.26 lakh in 2015 to Rs 9.65 lakh in 2020.

There was no change in the value of immovable assets of his wife while Kejriwal's immovable assets' worth increased from Rs 92 lakh to Rs 177 lakh.

The party functionaries said increase in Kejriwal's immovable assets' worth is due to the increased valuation of the same asset as in 2015.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.